DAWN - NASDAQ

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%

HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.22B

EPS-1.0400

P/E Ratio-20.70

Earnings Date05/13/2026

507.83M

Assets

-13%

3Y+45.0%

5Y+1012.0%

10Y+1758.0%

66.67M

Total Liabilities

-17%

3Y+292.0%

5Y+2930.0%

10Y+105.0%

441.16M

Total Equity

-12%

3Y+33.0%

5Y+915.0%

10Y-8607.0%

Day One Biopharmaceuticals, Inc. Funding & Solvency Profile

DAWN · NASDAQ

Current Assets

Cash & Cash Equivalents197.08M

Net Receivables26.73M

Inventory6.33M

Other Current Assets10.93M

Total Current Assets485 M

Non-Current Assets

Property, Plant & Equipment4.48M

Goodwill & Intangible Assets18.02M

Long-Term Investments0.00

Other Non-Current Assets230.00K

Total Non-Current Assets5 M

Total Assets

507.83M

Financial Health Analysis

Current Ratio

8.02x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.15x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

425 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Day One Biopharmaceuticals, Inc. Balance Sheet

DAWN • NASDAQ

Day One Biopharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	197.1M	125M	230.8M	85.3M	284.3M	43.7M	27.3M
Short-Term Investments	244M	406.8M	135.6M	257M	0.0	0.0	0.0
Cash & Short-Term Investments	441.1M	531.7M	366.3M	342.3M	284.3M	43.7M	27.3M
Net Receivables	26.7M	13.9M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	26.7M	13.9M	0.0	0.0	0.0	0.0	0.0
Inventory	6.3M	3.3M	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	9M	6.6M	4.6M	4M	84K	7K
Other Current Assets	10.9M	4.4M	2.4M	1M	1M	1.3M	0.0
Total Current Assets	485.1M	562.3M	375.3M	347.9M	289.4M	45.1M	27.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.5M	4.7M	560K	719K	284K	483K	0.0
Intangible Assets	18M	15.6M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	18M	15.6M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	230K	121K	214K	469K	169K	107K	0.0
Total Non-Current Assets	22.7M	20.5M	774K	1.2M	453K	590K	0.0
Total Assets	507.8M	582.8M	376M	349.1M	289.8M	45.7M	27.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.7M	3.3M	2.6M	260K	1.7M	202K	69K
Accounts Payable	3.7M	3.3M	2.6M	260K	1.7M	202K	69K
Accrued Expenses	0.0	13.9M	9.2M	6.1M	6.6M	1.6M	466K
Short Term Debt	174K	10K	408K	405K	204K	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	0.0	0.0	0.0	198K	0.0
Deferred Revenue	2M	1.6M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	54.6M	54.7M	17.4M	9.8M	104K	27K	1.5M
Total Current Liabilities	60.5M	73.5M	29.5M	16.6M	8.7M	2M	2M
NON-CURRENT LIABILITIES
Long Term Debt	2.6M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	3.2M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	3.5M	761K	0.0	0.0	0.0	0.0	30.5M
Total Non-Current Liabilities	6.1M	6.6M	0.0	408K	16K	204K	30.5M
Capital Lease Obligations	0.0	2.6M	0.0	408K	16K	402K	0.0
Total Liabilities	66.7M	80M	29.5M	17M	8.7M	2.2M	32.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	92M	5.5M
Common Stock	10K	10K	9K	7K	6K	2.6M	2M
Additional Paid-In Capital	0.0	1.1B	805.1M	601.8M	408.6M	0.0	0.0
Retained Earnings	-661.4M	-554.1M	-458.6M	-269.7M	-127.5M	-56.8M	-12.8M
Accumulated Other Comprehensive Income/Loss	65K	84K	9K	-71K	0.0	0.0	111.0
Other Total Stockholders' Equity	1.1B	0.0	0.0	0.0	0.0	0.0	-5.4M
Total Stockholders' Equity	441.2M	502.8M	346.5M	332M	281.1M	37.8M	-10.7M
Total Equity	441.2M	502.8M	346.5M	332M	281.1M	43.5M	-5.2M
Minority Interest	0.0	0.0	0.0	0.0	0.0	5.7M	5.5M
SUMMARY
Total Liabilities & Equity	507.8M	582.8M	376M	349.1M	289.8M	45.7M	27.3M
Total Investments	244M	406.8M	135.6M	257M	0.0	0.0	0.0
Total Debt	2.8M	2.6M	408K	813K	220K	402K	0.0
Net Debt	-194.3M	-122.4M	-230.4M	-84.4M	-284.1M	-43.3M	-27.3M
Shares Outstanding	102,675,502	102,675,502	102,675,502	102,675,502	102,675,502	102,675,502	102,675,502

SEC Filings

DAWN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 23, 2026	April 22, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 17, 2026	December 31, 2025	2025	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	March 09, 2026	January 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 06, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 24, 2025	November 24, 2025	2025	View Filing

Showing 1 to 10 of 93 filings

Related Guides

Blog Categories

Continue your DAWN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.